Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189693 | 0.95 | — | — | |
| SCHEMBL8074138 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL23531965 | 0.86 | — | — | |
| Hydroxyamine SCHEMBL8015019 | 0.86 | — | — | |
| Propane SCHEMBL28577487 | 0.82 | — | — | |
| Acetic Acid SCHEMBL7862250 | 0.82 | FFAR3 (0.47) | — | |
| Bicarbonate SCHEMBL28549988 | 0.79 | TSHR (0.41) | — | |
| Hydrochloric Acid SCHEMBL11060692 | 0.76 | — | — | |
| Acetic Acid SCHEMBL283399 | 0.76 | FFAR3 (0.50) | — | |
| Hydrochloric Acid SCHEMBL28230059 | 0.70 | GAA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450388-B | Composition for removing etching residues, and use method and application thereof | 弗萨姆材料美国有限责任公司 | 2025-03-21 | — | — | CN | claimed |
| CN-115960020-B | Caffeic acid nitrone compound and preparation method and application thereof | 深圳枫语生物医药科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117126118-A | Synthesis method of celecoxib | 上海应用技术大学 | 2023-11-28 | — | — | CN | claimed |
| CN-115960020-A | Caffeic acid nitrone compound and preparation method and application thereof | 深圳枫语生物医药科技有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-20220380705-A1 | Composition For Removing Etch Residues, Methods Of Using And Use Thereof | VERSUM MATERIALS US, LLC (US) | 2022-12-01 | — | — | US | claimed |
| CN-110396090-B | Imidazole alcohol tetrahydrocoptisane oxime conjugate and preparation method and application thereof | 西南大学 | 2022-09-09 | — | — | CN | claimed |
| EP-4034629-A1 | COMPOSITIONS FOR REMOVING ETCH RESIDUES, METHODS OF USING AND USE THEREOF | Versum Materials US, LLC (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114450388-A | Composition for removing etching residues, and use method and application thereof | 弗萨姆材料美国有限责任公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2021061922-A1 | COMPOSITIONS FOR REMOVING ETCH RESIDUES, METHODS OF USING AND USE THEREOF | VERSUM MATERIALS US, LLC (US) | 2021-04-01 | — | — | WO | claimed |
| CN-111676081-A | Antioxidant for reducing environmental pollution of lubricating oil and preparation method thereof | 安徽威驰化工有限责任公司 | 2020-09-18 | — | — | CN | claimed |
| CN-110283296-A | Difunctional polyurethane and the preparation method and application thereof | 中国科学院长春应用化学研究所 | 2019-09-27 | — | — | CN | claimed |
| CN-108849858-A | A kind of cornea middle term preserving fluid | 姚晓明 | 2018-11-23 | — | — | CN | claimed |
| EP-1250320-B1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2,4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2004-08-04 | — | — | EP | claimed |
| US-6689911-B2 | CONDENSATION REACTION OF A BENZYLALDEHYDE WITH N-TERT-BUTYLHYDROXYLAMINE, LARGE SCALE PRODUCTION | CENTAUR PHARMACEUTICALS, INC. | 2004-02-10 | — | — | US | claimed |
| US-20030069442-A1 | Novel process for the preparation of alpha-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | US | claimed |
| US-6512143-B1 | Salt formation by reaction of alkanoic acid with N-tert-butylhydroxylamine | ASTRAZENECA AB (CH) | 2003-01-28 | — | — | US | claimed |
| EP-1250320-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AstraZeneca AB (SE) | 2002-10-23 | — | — | EP | claimed |
| WO-2001051461-A1 | NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | claimed |
| EP-1095012-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | AstraZeneca AB (SE) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002848-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | claimed |